Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19 and BCMA CAR-T for Platelet Transfusion Refractoriness in Acute Leukemia
NCT04846439Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 CAR-T cells, BCMA CAR-T cells in platelet transfusion refractoriness (PTR), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
CD19 CAR-T cellsBCMA CAR-T cells
03
Conditions
platelet transfusion refractoriness (PTR)
Beyond the preview
Go deeper on NCT04846439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846439.